The promise of epigenomic therapeutics in pancreatic cancer

Gwen A. Lomberk, Juan Iovanna, Raul Urrutia

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is often viewed to arise primarily by genetic alterations. However, today we know that many aspects of the cancer phenotype require a crosstalk among these genetic alterations with epigenetic changes. Indeed, aberrant gene expression patterns, driven by epigenetics are fixed by altered signaling from mutated oncogenes and tumor suppressors to define the PDAC phenotype. This conceptual framework may have significant mechanistic value and could offer novel possibilities for treating patients affected with PDAC. In fact, extensive investigations are leading to the development of small molecule drugs that reversibly modify the epigenome. These new 'epigenetic therapeutics' discussed herein are promising to fuel a new era of studies, by providing the medical community with new tools to treat this dismal disease.

Original languageEnglish (US)
Pages (from-to)831-842
Number of pages12
JournalEpigenomics
Volume8
Issue number6
DOIs
StatePublished - Jun 1 2016

Fingerprint

Pancreatic Neoplasms
Epigenomics
Adenocarcinoma
Phenotype
Oncogenes
Neoplasms
Therapeutics
Gene Expression
Pharmaceutical Preparations

Keywords

  • chromatin
  • DNA methylation
  • DNMTs
  • epigenetics
  • HATs
  • HDACs
  • HMTs
  • noncoding RNAs
  • pancreatic cancer
  • therapeutics

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

The promise of epigenomic therapeutics in pancreatic cancer. / Lomberk, Gwen A.; Iovanna, Juan; Urrutia, Raul.

In: Epigenomics, Vol. 8, No. 6, 01.06.2016, p. 831-842.

Research output: Contribution to journalReview article

Lomberk, GA, Iovanna, J & Urrutia, R 2016, 'The promise of epigenomic therapeutics in pancreatic cancer', Epigenomics, vol. 8, no. 6, pp. 831-842. https://doi.org/10.2217/epi-2015-0016
Lomberk, Gwen A. ; Iovanna, Juan ; Urrutia, Raul. / The promise of epigenomic therapeutics in pancreatic cancer. In: Epigenomics. 2016 ; Vol. 8, No. 6. pp. 831-842.
@article{b1e87c746f14403ea178eed539f3fbb2,
title = "The promise of epigenomic therapeutics in pancreatic cancer",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is often viewed to arise primarily by genetic alterations. However, today we know that many aspects of the cancer phenotype require a crosstalk among these genetic alterations with epigenetic changes. Indeed, aberrant gene expression patterns, driven by epigenetics are fixed by altered signaling from mutated oncogenes and tumor suppressors to define the PDAC phenotype. This conceptual framework may have significant mechanistic value and could offer novel possibilities for treating patients affected with PDAC. In fact, extensive investigations are leading to the development of small molecule drugs that reversibly modify the epigenome. These new 'epigenetic therapeutics' discussed herein are promising to fuel a new era of studies, by providing the medical community with new tools to treat this dismal disease.",
keywords = "chromatin, DNA methylation, DNMTs, epigenetics, HATs, HDACs, HMTs, noncoding RNAs, pancreatic cancer, therapeutics",
author = "Lomberk, {Gwen A.} and Juan Iovanna and Raul Urrutia",
year = "2016",
month = "6",
day = "1",
doi = "10.2217/epi-2015-0016",
language = "English (US)",
volume = "8",
pages = "831--842",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - The promise of epigenomic therapeutics in pancreatic cancer

AU - Lomberk, Gwen A.

AU - Iovanna, Juan

AU - Urrutia, Raul

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Pancreatic ductal adenocarcinoma (PDAC) is often viewed to arise primarily by genetic alterations. However, today we know that many aspects of the cancer phenotype require a crosstalk among these genetic alterations with epigenetic changes. Indeed, aberrant gene expression patterns, driven by epigenetics are fixed by altered signaling from mutated oncogenes and tumor suppressors to define the PDAC phenotype. This conceptual framework may have significant mechanistic value and could offer novel possibilities for treating patients affected with PDAC. In fact, extensive investigations are leading to the development of small molecule drugs that reversibly modify the epigenome. These new 'epigenetic therapeutics' discussed herein are promising to fuel a new era of studies, by providing the medical community with new tools to treat this dismal disease.

AB - Pancreatic ductal adenocarcinoma (PDAC) is often viewed to arise primarily by genetic alterations. However, today we know that many aspects of the cancer phenotype require a crosstalk among these genetic alterations with epigenetic changes. Indeed, aberrant gene expression patterns, driven by epigenetics are fixed by altered signaling from mutated oncogenes and tumor suppressors to define the PDAC phenotype. This conceptual framework may have significant mechanistic value and could offer novel possibilities for treating patients affected with PDAC. In fact, extensive investigations are leading to the development of small molecule drugs that reversibly modify the epigenome. These new 'epigenetic therapeutics' discussed herein are promising to fuel a new era of studies, by providing the medical community with new tools to treat this dismal disease.

KW - chromatin

KW - DNA methylation

KW - DNMTs

KW - epigenetics

KW - HATs

KW - HDACs

KW - HMTs

KW - noncoding RNAs

KW - pancreatic cancer

KW - therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84978187321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978187321&partnerID=8YFLogxK

U2 - 10.2217/epi-2015-0016

DO - 10.2217/epi-2015-0016

M3 - Review article

C2 - 27337224

AN - SCOPUS:84978187321

VL - 8

SP - 831

EP - 842

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 6

ER -